NCT07537777 2026-04-17
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
Clinical Trials
10 trialsNCT07363512 2026-01-23
Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06031480 2023-09-11
FAITH
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04947371 2021-07-01
Adjuvant Therapy With Anlotinib for HCC
Shanghai Zhongshan Hospital
Phase 2 Withdrawn
NCT04665609 2021-03-04
Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
Chinese PLA General Hospital
Phase 3 Unknown
NCT04080154 2020-04-03
ALTER-H-002
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04157140 2019-12-03
Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
Beijing Ditan Hospital
Phase 2 Unknown
NCT03825705 2019-10-31
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT04066543 2019-08-26
TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT02809534 2016-09-07
ALTER0802
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown